Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-19T14:33:03.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical experience in the use of the antioestrogen tamoxifen in the treatment of breast cancer

Published online by Cambridge University Press:  05 December 2011

Helen J. Stewart
Helen J. Stewart
Affiliation:
Scottish Cancer Trials Office (MRC), The Medical School, Teviot Place, Edinburgh, EH8 9AG, Scotland, U.K.
Get access

Synopsis

The use of tamoxifen in the treatment of both metastatic and primary breast cancer is reviewed. In metastatic disease, tamoxifen slows progression in at least one-third of patients and is now the preferred first systemic therapy. Results from the larger trials of adjuvant tamoxifen are reviewed in relation to total dose and receptor status. It is suggested that variations in total dose may account for the variable results reported. Although benefit is not confined to those with tumours which are oestrogen-receptor (ER)-positive, the greatest chance of increasing disease-free survival would seem to be in those with high ER levels. Duration of tamoxifen and its effect within defined ER categories, with and without chemotherapy, are areas requiring further study by direct comparison.

Type
Research Article
Information
Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences , Volume 95: Oestrogen and the Human Breast , 1989 , pp. 231 - 237
Copyright
Copyright © Royal Society of Edinburgh 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cole, M. P., Jones, D. T. A. & Todd, I. D. H. 1971. A new antioestrogen agent in late breast cancer. An early appraisal of ICI 46474. British Journal of Cancer 25, 270–275.CrossRefGoogle Scholar
CRC Adjuvant Breast Trial Working Party 1988. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer – preliminary analysis. British Journal of Cancer 57, 604–607.Google Scholar
Cummings, F. J., Gray, R., Davis, T. E., Tormey, D. C., Harris, J. E., Falkson, G. G. & Arseneau, J. 1986. Tamoxifen versus placebo: Double-blind adjuvant trial in elderly women with stage II breast cancer. National Cancer Institute Monographs 1, 119–123.Google Scholar
Early Breast Cancer Trialists' Collaborative Group 1988. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. The New England Journal of Medicine 319, 1681–1692.CrossRefGoogle Scholar
Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E. R., Plotkin, D., Bowman, D., Sachs, S., Wolter, J., Frelick, R., Desser, R., LiCalzi, N., Geggie, P., Campbell, T., Elias, E. G., Prager, D., Koontz, P., Volk, H., Dimitrov, N., Gardner, B., Lerner, H., Shibata, H. and other NSABP investigators 1981. Treatment of primary breast cancer with chemotherapy and tamoxifen. The New England Journal of Medicine 305, 1–6.CrossRefGoogle ScholarPubMed
Fisher, B., Redmond, C., Brown, A., Fisher, E. R., Wolmark, N., Bowman, D., Plotkin, D., Wolter, J., Bornstein, R., Legault-Poisson, S., Saffer, E. A. & other NSABP Investigators 1986. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. Journal of Clinical Oncology 4, 459–471.Google Scholar
Fisher, B., Brown, A., Wolmark, N., Redmond, C., Wickerman, D. L., Wittliff, J., Dimitrov, N., Legault-Poisson, S., Schipper, H., Prager, D. and other NSABP investigators 1987. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel project clinical trial. Annals of Internal Medicine 106, 649–654.CrossRefGoogle ScholarPubMed
Glick, J. H. 1988. Meeting highlights: Adjuvant therapy for breast cancer. Journal of the National Cancer Institute 80, 471–476.Google Scholar
Goldhirsch, A. & Gelber, R. 1986. Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies. National Cancer Institute Monographs 1, 55–70.Google Scholar
Jackson, I. M. & Lowery, C. 1987. Clinical uses of antioestrogens. In Pharmacology and clinical uses of inhibitors of hormone secretion and action, eds. Furr, B. J. A. & Wakeling, A. E., pp. 87–105. London: Bailliere Tindall.Google Scholar
Mouridsen, H. T., Andersen, A. P., Brincker, H., Dombernowsky, P., Rose, C. & Andersen, K. W. 1986. Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present state of Danish Breast Cancer Cooperative Group Trials. National Cancer Institute Monographs 1, 115–118.Google Scholar
Nolvadex Adjuvant Trial Organisation (NATO) 1988. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. British Journal of Cancer 57, 608–611.Google Scholar
Ribeiro, G. & Swindell, R. 1988. The Christie hospital adjuvant tamoxifen trial – status at 10 years. British Journal of Cancer 57, 601–603.CrossRefGoogle ScholarPubMed
Scottish Breast Cancer Trials Committee (SBCTC) 1987. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii, 171–175.Google Scholar
Stewart, H. J., Forrest, A. P. M., Gunn, J. M., Hamilton, T., Langlands, A. O., McFadyen, I. J. & Roberts, M. M. 1980. The tamoxifen trial – a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. In Breast cancer. Experimental and clinical aspects, eds Mouridsen, H. T. & Palshof, T. European Journal of Cancer, Supplement 1, 83–88.Google Scholar
Tormey, D. C. 1987. Long-term adjuvant therapy with tamoxifen in breast cancer: How long is long? Annals of Internal Medicine 106, 762–763.Google Scholar